120
Participants
Start Date
October 19, 2022
Primary Completion Date
October 31, 2025
Study Completion Date
January 31, 2026
Placebo
Volume Matched Placebo
scp776 (1.9 mg/kg)
"Cohort 1 dose regimen:~Intravenous (IV) slow injection(s) over 2 minutes~\- 1.9 mg/kg"
scp776 (3.8 mg/kg)
"Cohort 2 dose regimen:~Intravenous (IV) slow injection(s) over 2 minutes~\- 3.8 mg/kg"
scp776 (4.8 mg/kg)
Cohort 3 dose regimen: Intravenous (IV) slow injection(s) over 2 minutes - 4.8 mg/kg
scp776 (all dose levels)
A composite group encompassing all participants who received any dose level of the investigational drug under evaluation.
Lennox Hill Hospital, New York
Northshore University Hospital, Manhasset
Penn State Health - M.S. Hershey Medical Center, Hershey
Jefferson Abington Hospital, Abington
Augusta University Medical Center, Augusta
University of Miami - Jackson Memorial Hospital, Miami
Marcus Neuroscience Institute, Boca Raton
The Ohio State University, Columbus
Mercy Health - St Vincent Medical Center, Toledo
Mercy Health - St Elizabeth Youngstown Hospital, Youngstown
University of Cincinnati, Cincinnati
Medical College of Wisconsin and Froedtert Hospital, Milwaukee
SSM Health DePaul Hospital, Bridgeton
St. Luke's Hospital of Kansas City, Kansas City
Houston Methodist Neurological Institute, Houston
HonorHealth Scottsdale Osborn Medical Center, Scottsdale
Banner University Medical Center /Univ of Arizona, Tucson
UNM Hospital, Albuquerque
Providence Portland Medical Center, Portland
Providence St. Vincent Medical Center, West Haven-Sylvan
Oregon Stroke Center at OHSU, Portland
Hartford Hospital, Hartford
Lead Sponsor
Silver Creek Pharmaceuticals
INDUSTRY